<DOC>
	<DOCNO>NCT01019551</DOCNO>
	<brief_summary>Viral eradication select HIV-infected patient possible intensive antiretroviral therapy plus immunomodulation</brief_summary>
	<brief_title>Therapeutic Intensification Plus Immunomodulation HIV-infected Patients</brief_title>
	<detailed_description>The overall strategy ERAMUNE 01 Trial treat select patient optimal synergistic antiretroviral regimen plus one immunomodulating agent . Among immunomodulating treatment candidate include therapy two functional class : 1 ) agent target actively replicate cell 2 ) agent activate latently infect cells31 . The novelty approach three-fold : first , use highly potent antiretroviral therapy combine drug different HIV enzymes target receptor different penetration cell , aim suppress virus truly undetectable level measure sophisticated viral quantification technique ; secondly , addition immunomodulatory therapy specifically target viral reservoir intensification strategy ; lastly , rigorous selection patient already low HIV reservoir measure peripheral blood HIV DNA content . To knowledge , type strategy implement . We believe strategy feasible .</detailed_description>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV1 infection , document licensed ELISA test kit confirm Western Blot time prior study entry . HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA acceptable alternative confirmatory test 18 ≤ Age ≤ 70 year At least 3 year suppressive ART without interruption ( less one month cumulative ) , ART treatment unchanged 3 month prior screen One HIV plasma viral load ( RNA ) document least 3 year prior entry , least 2 HIV plasma viral load ( RNA ) document per year thereafter HIV plasma viral load ( RNA ) ≤ 500 copies/ml least 3 year prior entry HIV plasma viral load ≤ 500 copies/ml ≥ 90 % measure thereafter HIV plasma viral load ( RNA ) limit detection value within past year . Note : assay use must lower limit detection 75 copies/ml less CD4+ count ≥ 350 cells/mm3 within 60 day entry 10 ≤ Proviral DNA ≤ 1000 copies/106 PBMCs within 60 day entry Documented laboratory value : Haemoglobin ≥ 10 g/dl , Platelets ≥ 100,000 per microliter , Hepatic transaminases ≤ 2.5 x ULN , Creatinine clearance ≥ 50 ml/min CockcroftGault equation All subject must agree participate conception process ( e.g . active attempt become pregnant impregnate , sperm donation , vitro fertilization ) , participate sexual activity could lead pregnancy , subject/partner must use least two reliable form contraceptive ( condom , without spermicidal agent , diaphragm cervical cap spermicide , IUD , hormonebased contraception ) , receive study treatment 6 week stop study treatment Ability willingness provide inform consent . Sexually active men woman practice least one form barrier birth control ( male partner use condom , female partner use condom , barrier contraception , etc ) Pregnancy document urine pregnancy test , lactate woman Hepatitis B antigen ( HBsAg ) positive Hepatitis C virus ( HCVAb ) positive HCV RNA detectable Previous use integrase inhibitor ( ie raltegravir ) CCR5 inhibitor ( ie maraviroc , vicriviroc ) . Use raltegravir nontreatment failure indication intensification toxicity switch allow , provide 1 ) virologic suppression maintain , raltegravir treatment 2 ) patient receive raltegravir treatment 6 month prior study entry . Previous immunologic therapeutic intervention ( e.g . IL2 , IL7 ) within past year Participation another clinical drug device trial last dose drug within past 30 day investigational medical device currently implant Diagnosis cancer within last 5 year ( except basal cell cutaneous cancer cutaneous KS require systemic therapy ) Comorbid condition expect survival less 12 month History hypersensitivity vaccination History autoimmune disease , systemic lupus erythematosis ( SLE ) Hashimoto 's thyroiditis Active drug alcohol use dependence , opinion center investigator , would interfere adherence study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Controlled viremia</keyword>
	<keyword>Viral reservoir</keyword>
	<keyword>Virus eradication</keyword>
	<keyword>Therapeutic intensification</keyword>
	<keyword>Immunointervention</keyword>
</DOC>